Key Takeaways
- • Biossil raised $153 million CAD ($70 million USD equivalent) in its latest funding round co-led by OpenAI and Founders Fund, emerging from stealth mode with a portfolio of 10 acquired drug molecules targeting life-threatening indications with unmet medical needs.
- • The Toronto-based AI-native biopharma company uses OpenAI's large language models to identify and repurpose drug candidates that failed in advanced clinical trials, dramatically reducing development timelines and costs compared to de novo drug discovery.
- • Two molecules from Biossil's portfolio are currently in advanced clinical trials, with the company targeting conditional regulatory approval for three resuscitated drugs to reach market, leveraging partnerships with 20+ universities and research institutions including Harvard, Mayo Clinic, and Hospital for Sick Children.
- • Founded in 2023 by Anthony Mouchantaf (formerly RBC Ventures) and Dr. Alexander Mosa (internal medicine specialist), Biossil represents a contrarian approach to biotech AI: instead of creating new molecules, the company mines the pharmaceutical industry's "discard pile" of failed compounds for repurposing opportunities.
- • This funding follows earlier seed rounds totaling $12 million CAD backed by investors including Peter Thiel and OpenAI, reflecting institutional confidence in AI-driven drug repurposing as a category distinct from earlier-stage AI drug discovery efforts.
Summary
Biossil Inc., a Toronto-based artificial intelligence biopharma company, announced a substantial $153 million CAD funding round ($70 million USD) co-led by OpenAI and Founders Fund. The capital raise marks the company's public emergence from stealth mode after three years of operating quietly while building its drug repurposing platform and portfolio. This funding event positions Biossil as a notable player in the intersection of AI and pharmaceutical development, with backing from prominent technology and venture capital investors.
The company's core innovation lies in its differentiated approach to combining AI with drug development. Rather than using machine learning to design entirely new molecular compounds—an approach that has not yet yielded an FDA-approved drug from well-funded competitors—Biossil employs OpenAI's large language models to systematically identify promising drug candidates from the pharmaceutical industry's vast repository of failed clinical trials. Over the past three years, the company has acquired or licensed 10 molecules from their original owners, with two currently advancing through late-stage clinical trials and three others targeted for conditional regulatory approval.
Founded in 2023 by Anthony Mouchantaf, a lawyer and former head of Royal Bank of Canada's venture capital strategy, and Dr. Alexander Mosa, a trained internal medicine specialist, Biossil targets life-threatening indications with urgent unmet medical needs. This business model offers substantial economic advantages: by starting with compounds that have already progressed to advanced clinical stages, Biossil circumvents years of early-stage research and potentially hundreds of millions in preclinical and Phase I/II costs. The strategy effectively converts the pharmaceutical industry's historical failures into development-stage assets with significantly de-risked trajectories.
The company has established clinical and research partnerships with more than 20 universities and institutions across North America and Europe, including Harvard University, the Mayo Clinic, Toronto's Hospital for Sick Children, and Denmark's Aarhus University. These partnerships provide both credibility and operational infrastructure for advancing trials and regulatory submissions. The institutional backing from OpenAI and Founders Fund, alongside earlier seed-stage investment from Peter Thiel, reflects confidence in drug repurposing with AI as an emerging category distinct from earlier generations of AI-native biotech companies that have attempted de novo drug discovery.
The company's core innovation lies in its differentiated approach to combining AI with drug development. Rather than using machine learning to design entirely new molecular compounds—an approach that has not yet yielded an FDA-approved drug from well-funded competitors—Biossil employs OpenAI's large language models to systematically identify promising drug candidates from the pharmaceutical industry's vast repository of failed clinical trials. Over the past three years, the company has acquired or licensed 10 molecules from their original owners, with two currently advancing through late-stage clinical trials and three others targeted for conditional regulatory approval.
Founded in 2023 by Anthony Mouchantaf, a lawyer and former head of Royal Bank of Canada's venture capital strategy, and Dr. Alexander Mosa, a trained internal medicine specialist, Biossil targets life-threatening indications with urgent unmet medical needs. This business model offers substantial economic advantages: by starting with compounds that have already progressed to advanced clinical stages, Biossil circumvents years of early-stage research and potentially hundreds of millions in preclinical and Phase I/II costs. The strategy effectively converts the pharmaceutical industry's historical failures into development-stage assets with significantly de-risked trajectories.
The company has established clinical and research partnerships with more than 20 universities and institutions across North America and Europe, including Harvard University, the Mayo Clinic, Toronto's Hospital for Sick Children, and Denmark's Aarhus University. These partnerships provide both credibility and operational infrastructure for advancing trials and regulatory submissions. The institutional backing from OpenAI and Founders Fund, alongside earlier seed-stage investment from Peter Thiel, reflects confidence in drug repurposing with AI as an emerging category distinct from earlier generations of AI-native biotech companies that have attempted de novo drug discovery.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.